Progress in Psychiatry

New England Journal of Medicine

Volumn 329, Issue 9, 1993, Pages 628-638

  Michels, Robert ^a   Marzuk, Peter M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADDICTION; AFFECTIVE PSYCHOSIS; ANXIETY DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENTAL DISEASE; MOOD DISORDER; NEUROSIS; PSYCHIATRY; PSYCHOLOGICAL ASPECT; REVIEW; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOLISM; ANTICHOLINERGIC EFFECT; ANXIETY NEUROSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MIXTURE; ELECTROCONVULSIVE THERAPY; HEART MUSCLE CONDUCTION DISTURBANCE; IMPOTENCE; MANIC DEPRESSIVE PSYCHOSIS; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

AFFECTIVE DISORDERS, PSYCHOTIC; ANXIETY DISORDERS; HIV INFECTIONS; HUMAN; MENTAL DISORDERS; MOOD DISORDERS; NEUROTIC DISORDERS; PSYCHIATRY; SUBSTANCE-RELATED DISORDERS; SUPPORT, U.S. GOV'T, P.H.S.;

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOMIPRAMINE; COCAINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

EID: 0027177695     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199308263290908     Document Type: Review

References (183)

1. Goodwin FK, Jamison KR. Evolution of the bipolar-unipolar concept. In: Goodwin FK, Jamison KR, eds. Manic-depressive illness. New York: Oxford University Press, 1990:56-73.
2. Himmelhoch JM, Mulla D, Neil JF, Detre TP, Kupfer DJ Incidence and significance of mixed affective states in a bipolar population. Arch Gen Psychiatry 1976; 33: 1062-1066
3. Coryell W, Lavori P, Endicott J, Keller M, VanEerdelwegh M Outcome in schizoaffective, psychotic and nonpsychotic depression: course during a six- to 24-month follow-up. Arch Gen Psychiatry 1984; 41: 787-791
4. Liebowitz MR, Quitkin FM, Stewart JW, Phenelzine v imipramine in atypical depression: a preliminary report. Arch Gen Psychiatry 1984; 41: 669-677
5. Rosenthal NE, Sack DA, Gillin JC, Seasonal affective disorder: a description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 1984; 41: 72-80
6. Kocsis JH, Frances A, Mann JJ, Imipramine for treatment of chronic depression. Psychopharmacol Bull 1985; 21: 698-700
7. Keller MB, Lavori PW, Endicott J, Coryell W, Klerman GL “Double depression”: two-year follow-up. Am J Psychiatry 1983; 140: 689-694
8. Goodwin FK, Jamison KR. The natural course of manic-depressive illness. In: Post RM, Ballenger JC, eds. Neurobiology of mood disorders. Baltimore: Williams & Wilkins, 1984:20-37.
9. Dunner DL, Fieve RR Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30: 229-233
10. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L Course of the manic-depressive cycle and changes caused by treatments. Pharmakopsychiatr Neuropsychopharmakol 1980; 13: 156-167
11. Goodwin FK, Jamison KR. Medical treatment of acute bipolar depression In: Goodwin FK, Jamison KR, eds. Manic-depressive illness. New York: Oxford University Press, 1990:630-64.
12. Cowdry RW, Wehr TA, Zis AP, Goodwin FK Thyroid abnormalities associated with rapid-cycling bipolar illness. Arch Gen Psychiatry 1983; 40: 414-420
13. Goodwin FK, Jamison KR. Medical treatment of manic episodes. In: Goodwin FK, Jamison KR, eds. Manic-depressive illness. New York: Oxford University Press, 1990:603-29.
14. Heninger GR, Charney DS, Delgado PL. Neurobiology of treatments for refractory depression. In: Tasman A, Goldfinger SM, Kaufmann CA, eds. Review of psychiatry. Vol. 9. Washington, D.C.: American Psychiatric Press, 1990:33-59.
15. Horowski R, Sastre-Y-Hernandez M Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of preliminary reports. Curr Ther Res 1985; 38: 23-29
16. Azmitia EC. The CNS serotonergic system: progression toward a collaborative organization. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:61-73.
17. Blier P, de Montigny C, Azzaro AJ Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system. J Pharmacol Exp Ther 1986; 237: 987-994
18. Chaput Y, de Montigny C, Blier P Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1986; 333: 342-348
19. Schildkraut JJ, Orsulak PJ, LaBrie RA, Toward a biochemical classification of depressive disorders. II. Application of multivariate discriminant function analysis to data on urinary catecholamines and metabolites. Arch Gen Psychiatry 1978; 35: 1436-1439
20. Schatzberg AF, Samson JA, Bloomingdale KL, Toward a biochemical classification of depressive disorders. X. Urinary catecholamines, their metabolites, and D-type scores in subgroups of depressive disorders. Arch Gen Psychiatry 1989; 46: 260-268
21. Potter WZ, Linnoila M Biochemical classifications of diagnostic subgroups and D-type scores. Arch Gen Psychiatry 1989; 46: 269-271
22. Board F, Persky H, Hamburg DA Psychological stress and endocrine functions: blood levels of adrenocortical and thyroid hormones in acutely disturbed patients. Psychosom Med 1956; 18: 324-333
23. Loosen PT, Prange AJ Jr Serum thyrotropin response to thyrotropin-releasing hormone in psychiatric patients: a review. Am J Psychiatry 1982; 139: 405-416
24. Gold PW, Goodwin FK, Chrousos GP Clinical and biochemical manifestations of depression: relation to the neurobiology of stress. N Engl J Med 1988; 319: 413-420
25. Nemeroff CB The role of corticotropin-releasing factor in the pathogenesis of major depression. Pharmacopsychiatry 1988; 21: 76-82
26. Checkley SA, Slade AP, Shur E Growth hormone and other responses to clonidine in patients with endogenous depression. Br J Psychiatry 1981; 138: 51-55
27. Kasper S, Wehr TA, Bartko JJ, Gaist PA, Rosenthal NE Epidemiological findings of seasonal changes in mood and behavior: a telephone survey of Montgomery County, Maryland. Arch Gen Psychiatry 1989; 46: 823-833
28. Kupfer DJ, Thase ME The use of the sleep laboratory in the diagnosis of affective disorders. Psychiatr Clin North Am 1983; 6: 3-25
29. Darcourt G, Souetre E, Pringuey D, Salvati E, Robert P, Belugou JL Circadian rhythms in depression. Psychiatr Psychobiol 1988; 3: Suppl: 85s-94s
30. Wehr TA, Wirz-Justice A, Goodwin FK, Duncan W, Gillin JC Phase advance of the circadian sleep-wake cycle as an antidepressant. Science 1979; 206: 710-713
31. Czeisler CA, Kronauer RE, Mooney JJ, Anderson JL, Allan SS Biologic rhythm disorders, depression, and phototherapy: a new hypothesis. Psychiatr Clin North Am 1987; 10: 687-709
32. Kupfer DJ, Spiker DG, Coble PA, Neil JF, Ulrich R, Shaw DH Depression, EEG sleep, and clinical response. Compr Psychiatry 1980; 21: 212-220
33. Post RM, Rubinow DR, Ballenger JC. Conditioning, sensitization, and kindling: implications for the course of affective illness. In: Post RM, Ballenger JC, eds. Neurobiology of mood disorders. Baltimore: Williams & Wilkins, 1984:432-66.
34. Post RM, Rubinow DR, Ballenger JC Conditioning and sensitisation in the longitudinal course of affective illness. Br J Psychiatry 1986; 149: 191-201
35. Klein DF, Gittelman R, Quitkin FM, et al. Diagnosis and drug treatment of psychiatric disorders: adults and children. Baltimore: Williams & Wilkins, 1980.
36. Chouinard G A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry 1985; 46: 32-37
37. Bech P A review of the antidepressant properties of serotonin reuptake inhibitors. Adv Biol Psychiatry 1988; 17: 58-69
38. Spiker DG, Perel JM, Hanin I, The pharmacological treatment of delusional depression: part II. J Clin Psychopharmacol 1986; 6: 339-342
39. Small JG, Klapper MH, Kellams JJ, Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry 1988; 45: 727-732
40. Markowitz J, Brown R, Sweeney J, Mann JJ Reduced length and cost of hospital stay for major depression in patients treated with ECT. Am J Psychiatry 1987; 144: 1025-1029
41. Task force report of the American Psychiatric Association. The practice of electroconvulsive therapy: recommendations for treatment, training and privileging. Washington, D.C.: American Psychiatric Association, 1990:61-2.
42. Bernstein JG. Handbook of drug therapy in psychiatry. 2nd ed. Littleton, Mass.: PSG Publishing, 1988:161-87.
43. Stratta P, Bolino F, Cupillari M, Casacchia M A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. Int Clin Psychopharmacol 1991; 6: 193-196
44. Simpson SG, DePaulo JR Fluoxetine treatment of bipolar II depression. J Clin Psychopharmacol 1991; 11: 52-54
45. Reimherr FW, Wood DR, Byerley B, Brainard J, Grosser BI Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984; 20: 70-72
46. Rosenthal NE, Sack DA, Skwerer RG, Jacobsen FM, Wehr TA Phototherapy for seasonal affective disorder. J Biol Rhythms 1988; 3: 101-120
47. Arana GW, Hyman SE. Handbook of psychiatric drug therapy. 2nd ed. Boston: Little, Brown, 1991:38-78.
48. Kupfer DJ, Carpenter LL, Frank E Possible role of antidepressants in precipitating mania and hypomania in recurrent depression. Am J Psychiatry 1988; 145: 804-808
49. Wehr TA, Goodwin FK Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987; 144: 1403-1411
50. Wehr TA, Sack DA, Rosenthal NE Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry 1987; 144: 201-204
51. Miller F, Menninger J Lithium-neuroleptic neurotoxicity is dose dependent. J Clin Psychopharmacol 1987; 7: 89-91
52. Post RM. Alternatives to lithium for bipolar affective illness. In: Tasman A, Goldfinger SM, Kaufmann CA, eds. Review of psychiatry. Vol. 9. Washington, D.C.: American Psychiatric Press, 1990:170-200.
53. Small JG, Klapper MH, Milstein V, Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991; 48: 915-921
54. Brown R U.S. experience with valproate in manic depressive illness: a multicenter trial. J Clin Psychiatry 1989; 50: Suppl: 13-16
55. Chouinard G, Young SN, Annable L Antimanic effect of clonazepam. Biol Psychiatry 1983; 18: 451-466
56. Gelenberg AJ, Kane JM, Keller MB, Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489-1493
57. Coxhead N, Silverstone T, Cookson J Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992; 85: 114-118
58. Frank E, Kupfer DJ, Wagner EF, McEachran AB, Cornes C Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression: contributing factors. Arch Gen Psychiatry 1991; 48: 1053-1059
59. Prien RF, Kupfer DJ, Mansky PA, Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984; 41: 1096-1104
60. Stark P, Hardison D A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985; 46: 53-58
61. Reimherr FW, Chouinard G, Cohn CK, Antidepressant efficacy of sertraline: a double-blind placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51: Suppl B: 18-27
62. Feighner J, Hendrickson G, Miller L, Stern W Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol 1986; 6: 27-32
63. Rudorfer MV, Potter WZ Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the “newer” versus the “older” drugs. Drugs 1989; 37: 713-738
64. Beasley CM Jr, Sayler ME, Bosomworth JC, Wernicke JF High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychopharmacol 1991; 11: 166-174
65. Golden RN, James SP, Sherer MA, Rudorfer MV, Sack DA, Potter WZ Psychoses associated with bupropion treatment. Am J Psychiatry 1985; 142: 1459-1462
66. Simpson GM, Lee JH, Cuculic Z, Kellner R Two dosages of imipramine in hospitalized endogenous and neurotic depressives. Arch Gen Psychiatry 1976; 33: 1093-1102
67. Quitkin FM, Rabkin JG, Ross D, McGrath PJ Duration of antidepressant drug treatment: what is an adequate trial? Arch Gen Psychiatry 1984; 41: 238-245
68. Lydiard RB Tricyclic-resistant depression: treatment resistance or inadequate treatment? J Clin Psychiatry 1985; 46: 412-417
69. Spiker DG, Weiss JC, Dealy RS, The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142: 430-436
70. McGrath PJ, Stewart JW, Harrison W, Quitkin FM Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 1987; 23: 169-172
71. Sackeim HA, Prudic J, Devanand DP. Treatment of medication-resistant depression with electroconvulsive therapy. In: Tasman A, Goldfinger SM, Kaufmann CA, eds. Review of psychiatry. Vol. 9. Washington, D.C.: American Psychiatric Press, 1990:91-115.
72. Stern WC, Harto-Truax N, Bauer N Efficacy of bupropion in tricyclic-resistant or intolerant patients. J Clin Psychiatry 1983; 44: 148-152
73. Ayd FJ, Zohar J. Psychostimulant therapy for chronic and treatment-resistant depression. In: Zohar J, Belmaker RH, eds. Treating resistant depression. New York: PMA Publishing, 1987:343-55.
74. De Montigny C, Grunberg F, Mayer A, Deschenes JP Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981; 138: 252-256
75. Goodwin FK, Prange AJ Jr, Post RM, Muscettola G, Lipton MA Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982; 139: 34-38
76. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989; 50: 447-449
77. Bergstrom RF, Peyton AL, Lemberger L Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992; 51: 239-248
78. Schmauss M, Kapfhammer HP, Meyr P, Combined MAO-inhibitor and tri-(tetra) cyclic antidepressant treatment in therapy resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 523-532
79. Diagnostic and statistical manual of mental disorders. 3rd ed. rev.: DSM-III-R. Washington, D.C.: American Psychiatric Association, 1987.
80. Lindberg FH, Distad LJ Post-traumatic stress disorders in women who experienced childhood incest. Child Abuse Negl 1985; 9: 329-334
81. Kendler KS, Heath A, Martin NG, Eaves LJ Symptoms of anxiety and depression in a volunteer twin population: the etiologic role of genetic and environmental factors. Arch Gen Psychiatry 1986; 43: 213-221
82. Paul SM Anxiety and depression: a common neurobiological substrate? J Clin Psychiatry 1988; 49: Suppl: 13-16
83. Papp LA, Coplan J, Gorman J. Neurobiology of anxiety. In: Tasman A, Riba MB, eds. Review of psychiatry. Vol. 11. Washington, D.C.: American Psychiatric Press, 1992:307-22.
84. Gorman JM, Askanazi J, Liebowitz MR, Response to hyperventilation in a group of patients with panic disorder. Am J Psychiatry 1984; 141: 857-861
85. Judd FK, Burrows GD, Norman TR The biological basis of anxiety: an overview. J Affect Disord 1985; 9: 271-284
86. Luxenberg JS, Swedo SE, Flament MF, Friedland RP, Rapoport J, Rapoport SI Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative X-ray computed tomography. Am J Psychiatry 1988; 145: 1089-1093
87. Pauls DL, Towbin KE, Leckman JF, Zahner GE, Cohen DJ Gilles de la Tourette's syndrome and obsessive-compulsive disorder. Arch Gen Psychiatry 1986; 43: 1180-1182
88. Pitman RK, Green RC, Jenike M, Mesulam MM Clinical comparison of Tourette's disorder and obsessive compulsive disorder. Am J Psychiatry 1987; 144: 1166-1171
89. Baxter LR Jr, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE Local cerebral glucose metabolic rates in obsessive-compulsive disorder: a comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 1987; 44: 211-218
90. Nordahl TE, Benkelfat C, Semple WE, Gross M, King AC, Cohen RM Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology 1989; 2: 23-28
91. Swedo SE, Schapiro MB, Grady CL, Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatry 1989; 46: 518-523
92. Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry 1988; 45: 177-185
93. Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JF Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 1990; 51: Suppl: 36-43
94. Boyd JH, Burke JD Jr, Gruenberg E, Exclusion criteria of DSM-III: a study of co-occurrence of hierarchy-free syndromes. Arch Gen Psychiatry 1984; 41: 983-989
95. Murphy DL. Serotonin and anxiety: an overview. Presented at the 140th Annual Meeting of the APA, Chicago, May 9-14, 1987.
96. Rickels K Buspirone in clinical practice. J Clin Psychiatry 1990; 51: Suppl: 51-54
97. Petracca A, Nisita C, McNair D, Melis G, Guerani G, Cassano GB Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone. J Clin Psychiatry 1990; 51: Suppl: 31-39
98. Jenike MA, Baer L An open trial of buspirone in obsessive-compulsive disorder. Am J Psychiatry 1988; 145: 1285-1286
99. Rapoport JL, Ryland DH, Kriete M Drug treatment of canine acral lick: an animal model of obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49: 517-521
100. Rapoport JL, Wise SP Obsessive-compulsive disorder: evidence for basal ganglia dysfunction. Psychopharmacol Bull 1988; 24: 380-384
101. Mavissakalian MR, Jones B, Olson S Absence of placebo response in obsessive-compulsive disorder. J Nerve Ment Dis 1990; 178: 268-270
102. Solomon K, Hart R Pitfalls and prospects in clinical research on antianxiety drugs: benzodiazepines and placebo -- a research review. J Clin Psychiatry 1978; 39: 823-831
103. Esman AH Psychoanalysis and general psychiatry: obsessive-compulsive disorder as paradigm. J Am Psychoanal Assoc 1989; 37: 319-336
104. Roy-Byrne PP, Lydiard RB. New developments in the psychopharmacologic treatment of anxiety. In: Roy-Byrne PP, ed. Anxiety: new findings for the clinician. Washington, D.C.: American Psychiatric Press, 1989:149-78.
105. Lydiard RB, Ballenger JC Antidepressants in panic disorder and agoraphobia. J Affect Disord 1987; 13: 153-168
106. Liebowitz MR Antidepressants in panic disorders. Br J Psychiatry Suppl 1989; 155: 46-52
107. Ballenger JC, Burrows GD, DuPont RL Jr, Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45: 413-422
108. Roy-Byrne PP, Cowley DS, eds. Benzodiazepines in clinical practice: risks and benefits. Washington, D.C.: American Psychiatric Press, 1991.
109. McTavish D, Benfield P Clomipramine: an overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 1990; 39: 136-153
110. Schneier FR, Liebowitz MR, Davies SO, Fluoxetine in panic disorder. J Clin Psychopharmacol 1990; 10: 119-121
111. Jenike MA, Baer L, Summergrad P, Weilburg JB, Holland A, Seymour R Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients. Am J Psychiatry 1989; 146: 1328-1330
112. Pigott TA, Pato MT, Bernstein SE, Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990; 47: 926-932
113. Goodman WK, Price LH, Delgado PL, Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990; 47: 577-585
114. Jenike MA, Baer L, Ballantine HT, Cingulotomy for refractory obsessive-compulsive disorder: a long-term follow-up of 33 patients. Arch Gen Psychiatry 1991; 48: 548-555
115. Laverdure B, Boulenger JP Beta-blocking drugs and anxiety: a proven therapeutic value. Encephale 1991; 17: 481-492
116. James IM, Burgoyne W, Savage IT Effect of pindolol on stress-related disturbances of musical performance: preliminary communication. J R Soc Med 1983; 76: 194-196
117. Brantigan CO, Brantigan TA, Joseph N Effect of beta blockade and beta stimulation on stage fright. Am J Med 1982; 72: 88-94
118. Neftel KA, Adler RH, Kappeli L, Stage fright in musicians: a model illustrating the effect of beta blockers. Psychosom Med 1982; 44: 461-469
119. Lockwood AH Medical problems of musicians. N Engl J Med 1989; 320: 221-227
120. Clark DB Performance-related medical and psychological disorders in instrumental musicians. Ann Behav Med 1989; 11: 28-34
121. Davidson J, Kudler H, Smith R, Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 1990; 47: 259-266
122. Reist C, Kauffman CD, Haier RJ, A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry 1989; 146: 513-516
123. Barlow DH, Craske MG, Cerny JA, Klosko JS Behavioral treatment of panic disorder. Behav Ther 1989; 20: 261-282
124. Foa EB, Steketee G, Grayson JB, Turner RM, Latimer PR Deliberate exposure and blocking of obsessive-compulsive rituals: immediate and long-term effects. Behav Ther 1984; 15: 450-472
125. Cooper NA, Clum GA Imaginal flooding as a supplementary treatment for PTSD in combat veterans: a controlled study. Behav Ther 1989; 20: 381-391
126. Butler G Issues in the application of cognitive and behavioral strategies to the treatment of social phobia. Clin Psychol Rev 1989; 9: 91-106
127. Shear MK, Fyer AJ, Ball G, Vulnerability to sodium lactate in panic disorder patients given cognitive-behavioral therapy. Am J Psychiatry 1991; 148: 795-797
128. Rounsaville BJ, Spitzer RL, Williams JB Proposed changes in DSM-III substance use disorders: description and rationale. Am J Psychiatry 1986; 143: 463-468
129. Cloninger CR Neurogenetic adaptive mechanisms in alcoholism. Science 1987; 236: 410-416
130. Schuckit MA Subjective responses to alcohol in sons of alcoholics and control subjects. Arch Gen Psychiatry 1984; 41: 879-884
131. Schuckit MA Ethanol-induced changes in body sway in men at high alcoholism risk. Arch Gen Psychiatry 1985; 42: 375-379
132. Schuckit MA, Gold E, Risch C Serum prolactin levels in sons of alcoholics and control subjects. Am J Psychiatry 1987; 144: 854-859
133. Schuckit MA, Gold E, Risch C Plasma cortisol levels following ethanol in sons of alcoholics and controls. Arch Gen Psychiatry 1987; 44: 942-945
134. Begleiter H, Porjesz B, Bihari B, Kissin B Event-related brain potentials in boys at risk for alcoholism. Science 1984; 225: 1493-1496
135. Kaplan RF, Hesselbrock VM, O'Connor S, DePalma N Behavioral and EEG responses to alcohol in nonalcoholic men with a family history of alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 873-885
136. Miller SB, Finn PR, Ditto B, Pihl RO Risk for hypertension in female members of multigenerational male-limited alcoholic families. Alcohol Clin Exp Res 1989; 13: 505-507
137. Frances RJ, Galanter M, Miller SI. Psychosocial approaches to treatment and rehabilitation. In: Tasman A, Hales RE, Frances AJ, eds. Review of psychiatry. Vol. 8. Washington, D.C.: American Psychiatric Press, 1989:341-58.
138. Fuller RK, Branchey L, Brightwell DR, Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986; 256: 1449-1455
139. Naranjo CA, Sellers EM. Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome. In: Galanter M, ed. Recent developments in alcoholism. Vol. 4. New York: Plenum Press, 1986:265-81.
140. Kraus ML, Gottlieb LD, Horwitz RI, Anscher M Randomized clinical trial of atenolol in patients with alcohol withdrawal. N Engl J Med 1985; 313: 905-909
141. Cushman P Jr, Forbes R, Lerner W, Stewart M Alcohol withdrawal syndromes: clinical management with lofexidine. Alcohol Clin Exp Res 1985; 9: 103-108
142. Hayashida M, Alterman AI, McLellan AT, Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. N Engl J Med 1989; 320: 358-365
143. Feldman DJ, Pattison EM, Sobell LC, Graham T, Sobell MB Outpatient alcohol detoxification: initial findings on 564 patients. Am J Psychiatry 1975; 132: 407-412
144. Dorus W, Kennedy J, Gibbons RD, Ravi SD Symptoms and diagnosis of depression in alcoholics. Alcohol Clin Exp Res 1987; 11: 150-154
145. Cregler LL, Mark H Medical complications of cocaine abuse. N Engl J Med 1986; 315: 1495-1500
146. Marzuk PM, Tardiff K, Leon AC, Stajic M, Morgan EB, Mann JJ Prevalence of recent cocaine use among motor vehicle fatalities in New York City. JAMA 1990; 263: 250-256
147. Marzuk PM, Tardiff K, Leon AC, Stajic M, Morgan EB, Mann JJ Prevalence of cocaine use among residents of New York City who committed suicide during a one year period. Am J Psychiatry 1992; 149: 371-375
148. Jarvik ME The drug dilemma: manipulating the demand. Science 1990; 250: 387-392
149. Scherer MA Intravenous cocaine: psychiatric effects, biological mechanisms. Biol Psychiatry 1988; 24: 865-885
150. Lowenstein DH, Massa SM, Rowbotham MC, Collins SD, McKinney HE, Simon RP Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med 1987; 83: 841-846
151. Gawin FH, Ellinwood EH Jr Cocaine and other stimulants: actions, abuse, and treatment. N Engl J Med 1988; 318: 1173-1182
152. O'Brien CP, Childress AR, Arndt IO, McLellan AT, Woody GE, Maany I Pharmacological and behavioral treatments of cocaine dependence: controlled studies. J Clin Psychiatry 1988; 49: Suppl: 17-22
153. Gawin F, Kleber HD Abstinence symptomatology and psychiatric diagnosis in cocaine abusers: clinical observations. Arch Gen Psychiatry 1986; 43: 107-113
154. Isner JM, Estes NAM III, Thompson PD, Acute cardiac events temporally related to cocaine abuse. N Engl J Med 1986; 315: 1438-1443
155. Levine SR, Brust JCM, Futrell N, Cerebrovascular complications of the use of the “crack” form of alkaloidal cocaine. N Engl J Med 1990; 323: 699-704
156. Pollack MH, Brotman AW, Rosenbaum JF Cocaine abuse and treatment. Compr Psychiatry 1989; 30: 31-44
157. Dackis CA, Gold MS New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev 1985; 9: 469-477
158. Gawin FH Chronic neuropharmacology of cocaine: progress in pharmacotherapy. J Clin Psychiatry 1988; 49: Suppl: 11-16
159. Atkinson JH Jr, Grant I, Kennedy CJ, Richman DD, Spector SA, McCutchan JA Prevalence of psychiatric disorders among men infected with human immunodeficiency virus: a controlled study. Arch Gen Psychiatry 1988; 45: 859-864
160. Perry S, Jacobsberg LB, Fishman B, Frances A, Bobo J, Jacobsberg BK Psychiatric diagnosis before serological testing for the human immunodeficiency virus. Am J Psychiatry 1990; 147: 89-93
161. Sacks M, Dermatis H, Looser-Ott S, Perry S Seroprevalence of HIV and risk factors for AIDS in psychiatric inpatients. Hosp Community Psychiatry 1992; 43: 736-737
162. Sacks MH, Silberstein C, Weiler P, Perry S HIV-related risk factors in acute psychiatric inpatients. Hosp Community Psychiatry 1990; 41: 449-451
163. Plant MA Alcohol, sex and AIDS. Alcohol 1990; 25: 293-301
164. Chaisson RE, Bacchetti P, Osmond D, Brodie B, Sande MA, Moss AR Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989; 261: 561-565
165. Fullilove RE, Fullilove MT, Bowser BP, Gross SA Risk of sexually transmitted disease among black adolescent crack users in Oakland and San Francisco, Calif. JAMA 1990; 263: 851-855
166. Ostrow DG, VanRaden MJ, Fox R, Kingsley LA, Dudley J, Kaslow RA Recreational drug use and sexual behavior change in a cohort of homosexual men: the Multicenter AIDS Cohort Study (MACS). AIDS 1990; 4: 759-765
167. Des Jarlais DC, Friedman SR, Casriel C Target groups for preventing AIDS among intravenous drug users. 2. The “hard” data studies. J Consult Clin Psychol 1990; 58: 50-56
168. Cooper JR Methadone treatment and acquired immunodeficiency syndrome. JAMA 1989; 262: 1664-1668
169. Perry S, Fishman B, Jacobsberg L, Young J, Frances A Effectiveness of psychoeducational interventions in reducing emotional distress after human immunodeficiency virus antibody testing. Arch Gen Psychiatry 1991; 48: 143-147
170. Price RW, Brew BJ The AIDS dementia complex. J Infect Dis 1988; 158: 1079-1083
171. Holland JC, Tross S The psychosocial and neuropsychiatric sequelae of the acquired immunodeficiency syndrome and related disorders. Ann Intern Med 1985; 103: 760-764
172. Perry S, Fishman B, Jacobsberg L, Frances A Relationships over 1 year between lymphocyte subsets and psychosocial variables among adults with infection by human immunodeficiency virus. Arch Gen Psychiatry 1992; 49: 396-401
173. Sartorius N AIDS and mental health. Irish J Psychol Med 1992; 9: 3-5
174. Perry SW Organic mental disorders caused by HIV: update on early diagnosis and treatment. Am J Psychiatry 1990; 147: 696-710
175. Ostrow D, Grant I, Atkinson H Assessment and management of the AIDS patients with neuropsychiatric disturbances. J Clin Psychiatry 1988; 49: Suppl: 14-22
176. Schmitt FA, Bigley JW, McKinnis R, Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988; 319: 1573-1578
177. Baer JW Study of 60 patients with AIDS or AIDS-related complex requiring psychiatric hospitalization. Am J Psychiatry 1989; 146: 1285-1288
178. Fernandez F, Adams F, Levy JK, Holmes VF, Neidhart M, Mansell PW Cognitive impairment due to AIDS-related complex and its response to psychostimulants. Psychosomatics 1988; 29: 38-46
179. Holmes VF, Fernandez F, Levy JK Psychostimulant response in AIDS-related complex patients. J Clin Psychiatry 1989; 50: 5-8
180. Marotta R, Perry S Early neuropsychological dysfunction caused by human immunodeficiency virus. J Neuropsychiatry Clin Neurosci 1989; 1: 225-235
181. Swenson JR, Erman M, Labell J, Extrapyramidal reactions: neuropsychiatric mimics in patients with AIDS. Gen Hosp Psychiatry 1989; 11: 248-253
182. Breitbart W, Marotta RF, Call P AIDS and neuroleptic malignant syndrome. Lancet 1988; 2: 1488-1489
183. Greenblatt M Psychiatry: the battered child of medicine. N Engl J Med 1975; 292: 246-250